Frag' FlorenceEvidenz. Klar. Anwendbar.
Uhr 7/8Sources Journal Tree
Easy Demo

Florence Themenbrowser · Onkologie · Seite 5

Was ist neu im Gesundheitswesen?

Entdecken Sie tatsächlich neu veröffentlichte Arbeiten aus Medizin, Pflege, Therapie, Public Health und Life Sciences. Sortiert nach Publikationsdatum, nicht nach Zitierhäufigkeit.

Themen erkunden

Aktuelle Forschung nach Fachgebiet

23 neue Nachweise auf dieser Seite Publiziert in den letzten 30 Tagen Neueste zuerst Crossref DOI
27.08.2026journal-article

Supportive Care in Cancer

Coordination of care in the context of primary brain tumors: Australian healthcare professionals’ exploration of the unspoken impact and clinical implications

Megan S. Jeon, Hannah Isaac, Joanne Shaw, Dianne M. Legge, Sharon He, Thomas Carlick, Eng-Siew Koh, Georgia K. B. Halkett, Brian Kelly, Mark B. Pinkham, Raymond J. Chan, Tamara Ownsworth, Haryana M. Dhillon, for the BRAINS Investigator Group, Meera Agar, Thea Blackler, Helen Haydon, Robyn Leonard, Anna Nowak, Kerryn Pike, Nicole Rankin, Ursula Sansom-Daly, Joel Rhee, Annie Miller, Kristi Milley, Mona Faris, Rachel Campbell, Katarzyna Lion, Jill Chen, Tiffany Fazon, Melinda Lyne, Sian Virtue-Griffiths, Jessica Buster, Emma McDougall

Abstract Aim People with primary brain tumor (PBT) and their families experience high distress and face challenges navigating their disease and treatment, healthcare systems, and/or survivorship. Quality brain tumor care coordination (BTCC) enables continuous, timely care according to the individual care needs of patients. We aimed to explore healthcare professionals’ (HCPs) practices and perceptions of BTCC. Methods We conducted semi-structured interviews with 12 HCPs (92% female) working with people with PBT from …

27.08.2026journal-article

Philosophical Transactions of the Royal Society B: Biological Sciences

Human epidermal growth factor receptor 2-directed therapeutics and their role in changing the natural course of breast cancer

Mark Sliwkowski

Abstract ErbB/EGFR (erythroblastosis B/epidermal growth factor receptor) family members play a role in driving the growth of various solid tumours. Therapeutic agents directed against two receptor family members, EGFR and human epidermal growth factor receptor 2 (HER2/ErbB2), show meaningful clinical benefit in solid tumours, including breast, lung, colorectal, gastric, head and neck. Clinically approved agents can be divided into three general categories: small-molecule tyrosine kinase inhibitors, monoclonal antib …

27.08.2026journal-article

Journal of Eating Disorders

Improvements in sleep, weight, and eating-disorder symptoms following off-label leptin treatment in an adolescent with chronic anorexia nervosa and insomnia: a case report

Alexander Dück, Hang Zhu, Judith Melinat, Monika Kruzer, Christoph Berger, Michael Kölch, Martin Reinhardt, Hannes Brehme, Annelie Zimmermann, Linda Frintrop, Olaf Reis

Abstract We report off-label administration of human recombinant leptin (metreleptin) over a 12-day period in a 17-year-old female adolescent with chronic anorexia nervosa (AN) and clinically significant insomnia. Two observation windows are distinguished throughout: a short-term window between day 1 (pre) and day 12 (post) of dosing, and a longer-term window between day 12 and the two-month follow-up (d + 60), capturing both changes temporally associated with leptin administration and the course of continued weigh …

27.08.2026journal-article

Effectiveness of Adherence-Focused Interventions and Contemporary Predictors of Treatment Success in Drug-Sensitive Tuberculosis in Low- and Middle-Income Countries: A Systematic Review and Meta-Analysis (2018–2023)

Effectiveness of Adherence-Focused Interventions and Contemporary Predictors of Treatment Success in Drug-Sensitive Tuberculosis in Low- and Middle-Income Countries: A Systematic Review and Meta-Analysis (2018–2023)

Moh. Khairul Hassan

Drug-sensitive tuberculosis (TB) treatment success in low- and middle-income countries (LMICs) has historically fallen short of the WHO's 85% benchmark. Predictors of treatment success are well described, but newer adherence-focused interventions, including digital tools introduced since 2018, have not been synthesized alongside contemporary evidence on predictors. Methods. A systematic review and meta-analysis followed PRISMA guidelines and covered the period from January 2018 to April 2023 across PubMed, ScienceD …

27.08.2026journal-article

Neuro-Oncology

101 Independent replication and validation of nanopore-based long read sequencing and methylome classification for rapid brain tumour diagnosis

Vassili Crispi, Luke Ames, Joanne Stockton, Sana Manan, Nicola Chadderton, Lisa James, Sahar Sanai, Tracy Bright, Rajwinder Rai, Santosh Nagaraju, Ute Pohl, Philipe Taniere, Andrew Beggs, Colin Watts, Victoria Wykes

Abstract Introduction Integrated histopathological-molecular analysis is essential to diagnose and guide precision therapies in brain tumours. Whilst standard of care (SoC) diagnostics takes weeks, long read sequencing (LRS) on Oxford Nanopore Technology (ONT) platform and bioinformatics research tools provide rapid diagnosis within hours/days. We independently replicated ONT-LRS diagnostic assay within the NHS. Methods Patients undergoing brain tumour surgery were prospectively consented for surplus tissue samplin …

27.08.2026journal-article

Neuro-Oncology

42 The case for rapid molecular diagnosis; The power of PPIE

Simon Newman, Rachel Roberts, Helen Bulbeck, Lillie Pakzad-Shahabi, Ameeta Retzer, Stuart Smith, Matt Loose, Victoria Wykes

Abstract Introduction With over a hundred distinct molecular diagnostic entities, timely and accurate diagnosis is essential. A Network of Excellence (NoE) is being proposed to deliver rapid (<3 days) molecular diagnosis. To inform the funding application for the NoE, a PPIE survey was developed as a joint initiative between The Brain Tumour Charity, Brainstrust, BERTI-West Midlands and Imperial College London. Methods The survey ran between 13-19 January 2026 and was shared through major brain tumour patient an …

27.08.2026journal-article

Neuro-Oncology

68 Adjuvant chemotherapy in WHO Grade 2 Astrocytoma: Retrospective Analysis at NNUH to Inform a Multicentre Comparative Study

Clare Hannon, Rebecca Brooks, Pinelopi Gkogkou, Andrew Ho

Abstract Background The optimal adjuvant chemotherapy for WHO grade 2 astrocytoma remains uncertain. UK NICE guidance recommends radiotherapy followed by PCV chemotherapy in higher-risk patients; however, temozolomide (TMZ) is sometimes used due to efficacy data in grade 3 astrocytoma as well as its favourable tolerability and ease of administration. No randomised trials directly compare PCV and TMZ in this population, and real-world data on toxicity, treatment adherence, and outcomes remain limited. Retrospective …

27.08.2026journal-article

Neuro-Oncology

145 Implementing Vorasidenib in Clinical Practice: A Single-Centre Real-World Service Evaluation

Brooke Smart, Lorna Raymond, Antonia Creak, Liam Welsh, Ella Nicklin, Matteo Isolani, Ozofu Omuemu, Francesca Solda, Nicola Rosenfelder

Abstract Introduction The phase 3 INDIGO trial demonstrated significantly improved progression-free survival with Vorasidenib in patients with residual/recurrent IDH-mutant grade 2 oligodendroglioma and astrocytoma, supporting its integration into routine neuro-oncology practice. We undertook a real-world service evaluation at the Royal Marsden Hospital to assess toxicity, monitoring burden, and implications for wider UK implementation ahead of the anticipated appraisal by the National Institute for Health and Care …

27.08.2026journal-article

Canadian Liver Journal

Impact of direct-acting antiviral treatment on time and out-of-pocket costs for hepatitis C patients

Yasmin A Saeed, Arcturus Phoon, Josephine F Wong, Kate Mason, Seff Pinch, Valérie Martel-Laferrière, Julie Bruneau, Jordan J Feld, Zeny Feng, Samuel S Lee, Jeff Powis, Beate Sander, William WL Wong

Abstract Background: Direct-acting antiviral (DAA) therapies have transformed care for chronic hepatitis C (CHC); however, the effect of DAA therapy on patient-borne costs is unclear. These costs can pose a substantial burden for patients and their families—even in a publicly funded health system. We estimated the patient-borne costs associated with CHC and the impact of DAA therapy on these costs. Methods: We recruited patients with CHC who were prescribed DAA therapy at two specialized liver clinics and five low- …

27.08.2026journal-article

Neuro-Oncology Practice

Interventions Addressing Informational Needs of Adults with Primary Malignant Brain Tumors: A Systematic Review

Maria Camilla Mathiasen, Florien Boele, Georgia K B Halkett, Anders Overby Sjøstrøm, Dorte Schou Nørøxe, Helle Pappot, Karin Piil

Abstract Background Patients with primary malignant brain tumors (PMBT) and their caregivers face informational challenges due to cognitive impairment, emotional distress, and complex treatment trajectories. Although informational interventions have been developed, effectiveness and scope remain unclear. This systematic review aimed to synthesise evidence on interventions addressing informational needs in this population. Methods Five databases (MEDLINE, Embase, Cochrane Library, CINAHL, PsycINFO) were searched for …

27.08.2026journal-article

Clinical Cancer Research

Adrenergic regulation of cancer immunity

Jingjing Zhu, Pierre-Hubert Desimpel, Constance Gérard, Benoit J. Van den Eynde

Abstract The nervous and immune systems engage in extensive bidirectional crosstalk that shapes tumor progression and therapeutic response. Among the neuro-immune pathways involved in cancer, adrenergic receptor signaling has emerged as a key regulator of the tumor microenvironment. In this review, we summarize current understanding of the distinct roles of β- and α2-adrenergic receptor signaling in cancer immunity and their therapeutic implications. β2-adrenergic receptor signaling promotes immune suppression by i …

27.08.2026journal-article

Frontiers in Public Health

Lung cancer screening in occupational settings: a scoping review

Edelqueen Ijeoma Okoro, Helena Keller, Felix Greiner, Jan Heidrich, Volker Harth

Background Lung cancer is the leading cause of cancer-related mortality worldwide. It is often asymptomatic until advanced stages, resulting in delayed diagnosis and poor survival. Screening enables early detection and reduces mortality. Multiple occupational and environmental exposures have been linked to lung cancer, and some guidelines recommend their inclusion in risk assessment. This review aims to map the existing evidence on lung cancer screening (LCS) in occupational settings. Methods This review followed J …

27.08.2026journal-article

Endocrine-Related Cancer

PSIP1::TBL1X : a recurrent gene fusion in pancreatic neuroendocrine tumors

Daniel Ackerman, Elisabeth R. Seyferth, Wuyan Li, Julia E. Youngman, Jelsia N. Cottone, Cecilia A. Wright, Robyn T. Sussman, Abashai A. Woodard, David C. Metz, Bryson W. Katona, Michael C. Soulen, Daniel M. DePietro, Jennifer R. Eads, Terence P. Gade

Abstract Effective treatment of metastatic neuroendocrine tumors (NETs) is limited by a lack of targeted therapies and clinically useful predictive biomarkers. We applied complementary genomic profiling technologies, including optical genome mapping (OGM) and whole exome sequencing (WES), to 70 liver metastases of NETs from multiple anatomical primary sites to identify actionable genomic alterations. We detected recurrent fusions involving TBL1X (PSIP1::TBL1X) and BEND2 (CHD7::BEND2 and NEO1::BEND2) by OGM in pancr …

27.08.2026journal-article

Cancers

Serum SAMD9 as a Potential Prognostic Biomarker for Pancreatic Cancer

Xingyu He, Ying Zheng, Xunjie Cao, Jianhao Zhang, Yang Yang, Qing Zhu

Background: Pancreatic cancer (PC) is one of the most aggressive malignancies and remains a leading cause of cancer-related mortality worldwide. Despite advances in diagnosis and treatment, reliable biomarkers for detection and prognostic assessment remain limited. Sterile alpha motif domain containing 9 (SAMD9) has been implicated in several human malignancies, but its clinical significance in PC has not been fully elucidated. Therefore, this study aimed to investigate the diagnostic and prognostic value of SAMD9 …

27.08.2026journal-article

Neuro-Oncology

15 Promoting the need for a dedicated Neuro‑Oncology Occupational Therapy Service at QEHB: A Quality Improvement Project

Megan Jones

Abstract Introduction This project highlights the role of Occupational Therapists (OTs) in supporting the neuro‑oncology patient population at the Queen Elizabeth Hospital Birmingham (QEHB). Although the OT service is well established, there is currently no structured pathway to ensure that patients with brain cancer receive optimal pre‑ and post‑operative management. This patient group is also at risk of inadequate follow‑up after discharge, re-affirming the need for service development and targeted investment. Me …

27.08.2026journal-article

Cancers

Beyond Thrombus Level: Increased Surgical Complexity, Nutritional Status, and Postoperative Complications Shape Outcomes in Renal Cell Carcinoma with Venous Tumor Thrombus—A 14-Year Single-Center Experience

Zuzanna Korbecka, Beata Jabłońska, Michał Serafin, Wiktoria Kuczmik, Bartosz Pomianowski, Karolina Blady, Robert Król

Background: Renal cell carcinoma (RCC) with venous tumor thrombus (VTT) (RCC-VTT) represents a surgically challenging entity with heterogeneous prognosis. While the level of thrombus has traditionally been considered a key prognostic factor, its independent impact remains controversial. Aim: The aim of the study was to evaluate perioperative and oncological outcomes in patients with RCC-VTT, as well as to assess the impact of VTT level on the surgical and oncological outcomes, and identify predictors of postoperati …

27.08.2026journal-article

Frontiers in Medicine

Advanced and underlying therapeutic strategies in transformed small cell lung cancer

Mingfeng Wei, Zheng Li, Kaiyuan Zhu, Shixiang Guo, Lefei Hu, Fuzhi Yang, Xiaoyu Chen, Xuelin Zhang, Shuai Jiang, Xunxia Zhu, Xiaoyong Shen

Transformed small-cell lung cancer (T-SCLC) is a clinically important form of histologic transformation and a mechanism of acquired resistance in non-small-cell lung cancer (NSCLC). It is associated with poor prognosis, with a median overall survival of only about 9–13 months. This review summarizes recent advances in the mechanisms, diagnosis, monitoring, and treatment of T-SCLC. Repeat biopsy remains the gold standard for confirming histologic transformation, whereas molecular profiling and liquid biopsy may faci …

27.08.2026journal-article

Cancer Immunology Research

CD4+ T Cells Play Distinct Roles during the Priming versus Effector Phases of Immune Checkpoint Therapy–Dependent Tumor Elimination by CD8+ T Cells

Samuel Ameh, Derek J. Theisen, Mahima Thapa, Jackson S. Turner, Abhinav Rangarajan, Christopher A. Nelson, Aaron J. Schmitz, Yuang Song, Ruan F. Vieira Medrano, Cora D. Arthur, J. Michael White, Kathleen C.F. Sheehan, Daved H. Fremont, Ali H. Ellebedy, Hussein Sultan, Robert D. Schreiber

Abstract It is well established that CD4+ T cells play a critical role in facilitating immune checkpoint therapy (ICT). Although CD4+ T-cell function in lymph nodes during CD8+ T-cell priming has been well investigated, their requirement at the effector phase in the tumor is only now beginning to be appreciated. Herein, we used our major histocompatibility complex class II–negative (MHC-II−) sarcoma models to confirm that CD4+ T cells are essential not only during T-cell priming but also to maintain T-cell effector …

27.08.2026journal-article

Diagnostics

Toward AI-Assisted Precision Diagnostics in Breast Cancer: Source-Group-Preserving Evaluation of Class-Imbalance Strategies for Ordered ER-IHC Segmentation

Md Saiful Arefin, Mohammad Saiful Islam, Md Serajun Nabi, Rashadul Islam Sumon, Maria Lapina, Vitalii Lapin, Mohammed Muthanna

Background/Objectives: Estrogen receptor immunohistochemistry (ER-IHC) exhibits heterogeneous staining and substantial class imbalance, complicating segmentation of ordered expression categories. We evaluated whether class weighting, minority-focused crop sampling, adaptive minority curriculum (AMC), and Focal–Tversky optimization improved a common ResUNet-DS backbone for segmenting background/non-target pixels and C1 ER-negative, C2 weak-positive, C3 moderate-positive, and C4 strong-positive foreground categories. …

27.08.2026journal-article

World Journal of Gastrointestinal Surgery

Clinical effects of nutritional risk screening 2002-guided individualized nutritional intervention in postoperative colorectal cancer patients: A time-period comparison study

Xiu-Lian Zhang, Qing-Qi Hong, Li-Zhen Lin

BACKGROUND Postoperative malnutrition prevalence among colorectal cancer (CRC) patients is high and has an essential impact on the recovery process and quality of life. Traditional models of nutritional management are not individualized and have limited efficacy. New insights have emerged from the application of enhanced recovery after surgery concept that can help us improve patients post-operative nutritional status. AIM To investigate the effects of nutritional risk (NR) assessment associated with individualized …

27.08.2026journal-article

Neuro-Oncology

30 Role of post-operative radiotherapy following neurosurgical resection of brain metastases – 5-year single centre retrospective analysis

Lauren Best, Laura Palles-Clark, Sara Walters, Rebecca John, James Powell, Jillian Maclean, Kathrin Whitehouse, George Eralil, Najmus Sahar Iqbal

Abstract Introduction Surgical resection of brain metastases offers reduced local recurrence, improved functional independence, and improved overall survival. NICE does not recommend adjuvant stereotactic radiosurgery (SRS) or whole brain radiotherapy (WBRT) following complete surgical resection of brain metastasis. Method 140 patients were identified from the South Wales Neuro-Oncology MDT between 2018 and 2023 who underwent neurosurgical resection for brain metastases. Demographics including primary cancer, prese …

27.08.2026journal-article

Muğla Sıtkı Koçman Üniversitesi Tıp Dergisi

A Hybrid Approach to the Surgical Treatment of a Large Prolapsed Pedunculated Submucous (Nascent) Leiomyoma: Transvaginal Myomectomy Followed by Operative Hysteroscopy

Bekir Sıtkı İsenlik, Orkun Han, Zeynep Ozturk Inal, Hasan İnal

Uterine leiomyomas are the most common benign pelvic tumors in women. In rare cases, submucous leiomyomas may prolapse through the cervical canal into the vagina; these are referred to as nascent leiomyomas. The standard surgical treatment is transvaginal myomectomy, although hysteroscopic management may be required when complete removal of the pedicle base cannot be safely achieved by the vaginal route alone. We report the case of a 36-year-old nulligravid woman presenting with hypermenorrhea, pelvic pain, and fat …

27.08.2026journal-article

Gastric Cancer

Phase II study of mFOLFOX6 in advanced gastric cancer patients with severe peritoneal metastases (WJOG10517G), including an individual patient data comparison with JCOG1108/WJOG7312G

Toshiki Masuishi, Hiroki Hara, Takayuki Ando, Takeshi Kawakami, Yoshiyuki Yamamoto, Naotoshi Sugimoto, Kazuhiro Shiraishi, Taito Esaki, Yuji Negoro, Takao Tsuzuki, Hiroaki Sawai, Masato Nakamura, Takashi Inagaki, Yudai Shinohara, Kentaro Kawakami, Seiichiro Mitani, Kenji Tsuchihashi, Chihiro Kondoh, Hiroo Katsuya, Osamu Maeda, Yuriko Fujita, Kenichi Yoshimura, Masanori Terashima, Takako Eguchi Nakajima, Kei Muro

Abstract Background Advanced gastric cancer patients with severe peritoneal metastases, defined as massive ascites throughout the abdominal cavity and/or inadequate oral intake requiring intravenous infusion support, have been excluded from pivotal clinical trials. Methods This phase II trial evaluated mFOLFOX6 in HER2-negative, chemotherapy-naive advanced gastric cancer patients with severe peritoneal metastases. The primary endpoint was overall survival (OS); secondary endpoints included ascites response rate amo …